BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29693179)

  • 1. miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.
    Wang X; Qiu H; Tang R; Song H; Pan H; Feng Z; Chen L
    Oncol Rep; 2018 Jun; 39(6):2635-2643. PubMed ID: 29693179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
    Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
    PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
    Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
    Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
    [No Abstract]   [Full Text] [Related]  

  • 9. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
    Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
    Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
    Tan H; He Q; Gong G; Wang Y; Li J; Wang J; Zhu D; Wu X
    Int J Oncol; 2016 Jan; 48(1):181-90. PubMed ID: 26575700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
    Kang J; Zhong Y; Tian W; Li J; Li X; Zhai L; Hou H; Li D
    Int J Oncol; 2021 May; 58(5):. PubMed ID: 33760108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
    Liu F; Zhuang L; Wu R; Li D
    J BUON; 2019; 24(5):1905-1912. PubMed ID: 31786854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer.
    Kong P; Chen L; Yu M; Tao J; Liu J; Wang Y; Pan H; Zhou W; Wang S
    Cell Death Dis; 2018 Oct; 9(11):1059. PubMed ID: 30333478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of β3 integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk/Ets‑1 network in triple-negative breast cancer.
    Li W; Liu C; Zhao C; Zhai L; Lv S
    Int J Oncol; 2016 Mar; 48(3):1155-64. PubMed ID: 26781040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ROR1 has prognostic significance in triple negative breast cancer.
    Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
    Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.